Cerus Corporation (CERS) Financial Ratios
29 years of historical data (1997–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
↑
61.37
↑+55% vs avg
5yr avg: 39.71
30Y Low33.4·High46.1
P/B Ratio
↓
7.66
-7% vs avg
5yr avg: 8.27
30Y Low0.7·High150.6
ROE
↑
-25.6%
↓+46% vs avg
5yr avg: -47.6%
30Y Low-249%·High46%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CERS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cerus Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 61.4x P/FCF, 55% above the 5-year average of 39.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $523M | $393M | $284M | $389M | $644M | $1.2B | $1.1B | $590M | $668M | $366M | $443M |
| Enterprise Value | $600M | $470M | $362M | $474M | $696M | $1.2B | $1.2B | $620M | $669M | $382M | $440M |
| P/E Ratio → | -31.83 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.54 | 1.90 | 1.58 | 2.49 | 3.98 | 8.91 | 12.34 | 7.90 | 10.96 | 8.40 | 11.91 |
| P/B Ratio | 7.66 | 6.04 | 5.00 | 7.29 | 9.40 | 13.62 | 10.93 | 10.34 | 7.90 | 9.39 | 7.67 |
| P/FCF | 61.37 | 46.07 | 33.35 | — | — | — | — | — | — | — | — |
| P/OCF | 46.04 | 34.56 | 25.02 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CERS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.28 | 2.01 | 3.03 | 4.30 | 9.21 | 12.67 | 8.30 | 10.98 | 8.77 | 11.83 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 55.11 | 42.49 | — | — | — | — | — | — | — | — |
CERS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cerus Corporation earns an operating margin of -17.6%. Operating margins have expanded from -19.2% to -17.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -25.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.5% | 53.5% | 55.2% | 55.3% | 53.7% | 51.5% | 55.2% | 55.2% | 48.1% | 48.3% | 45.4% |
| Operating Margin | -17.6% | -17.6% | -7.9% | -19.2% | -21.0% | -37.4% | -63.5% | -88.7% | -90.3% | -132.0% | -165.3% |
| Net Profit Margin | -7.6% | -7.6% | -11.6% | -24.0% | -26.4% | -41.6% | -65.1% | -95.4% | -94.5% | -139.1% | -169.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.6% | -25.6% | -37.9% | -61.5% | -55.5% | -57.4% | -74.4% | -100.6% | -93.3% | -125.3% | -82.5% |
| ROA | -7.4% | -7.4% | -10.5% | -18.0% | -18.8% | -23.7% | -30.9% | -43.3% | -44.0% | -60.1% | -51.8% |
| ROIC | -19.7% | -19.7% | -7.8% | -17.5% | -20.9% | -28.4% | -39.7% | -57.7% | -58.7% | -78.7% | -93.8% |
| ROCE | -28.1% | -28.1% | -10.6% | -26.0% | -26.2% | -30.5% | -42.2% | -58.6% | -59.2% | -75.8% | -63.3% |
CERS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $77M ($97M total debt minus $20M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.49 | 1.49 | 1.72 | 1.80 | 1.27 | 1.02 | 0.64 | 1.13 | 0.35 | 0.77 | 0.34 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.19 | 1.37 | 1.58 | 0.75 | 0.45 | 0.29 | 0.52 | 0.01 | 0.41 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 9.03 | 9.13 | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.36 | -4.36 | -1.34 | -3.45 | -6.26 | -9.98 | -14.90 | -11.05 | -13.31 | -17.76 | -24.66 |
CERS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.73x means Cerus Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.17x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.14x to 1.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.73 | 1.73 | 2.39 | 2.14 | 1.45 | 2.38 | 3.06 | 2.55 | 2.79 | 3.89 | 3.50 |
| Quick Ratio | 1.17 | 1.17 | 1.79 | 1.55 | 1.21 | 2.04 | 2.67 | 2.16 | 2.53 | 3.26 | 3.03 |
| Cash Ratio | 0.82 | 0.82 | 1.26 | 0.98 | 0.87 | 1.65 | 2.23 | 1.70 | 2.23 | 2.62 | 2.66 |
| Asset Turnover | — | 0.93 | 0.90 | 0.79 | 0.74 | 0.55 | 0.42 | 0.45 | 0.37 | 0.44 | 0.36 |
| Inventory Turnover | 1.71 | 1.71 | 2.12 | 1.75 | 2.58 | 2.37 | 1.77 | 1.71 | 2.34 | 1.56 | 1.62 |
| Days Sales Outstanding | — | 53.78 | 60.29 | 82.87 | 77.54 | 70.09 | 84.05 | 82.55 | 52.45 | 104.01 | 67.42 |
CERS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cerus Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.6% | 2.2% | 3.0% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $191M | $185M | $180M | $177M | $171M | $164M | $140M | $132M | $108M | $102M |
Peer Comparison
Compare CERS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CERSYou | $523M | -31.8 | — | 61.4 | 53.5% | -17.6% | -25.6% | -19.7% | — |
 TXG | $3B | -64.1 | — | 22.2 | 69.1% | -17.2% | -5.8% | -17.9% | — |
 BLFS | $1B | -92.5 | — | 106.2 | 64.6% | -12.6% | -3.4% | -2.8% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 HAE | $3B | 26.5 | 22.4 | 9.7 | 59.0% | 11.7% | 11.4% | 6.5% | 7.8 |
 TER | $55B | 101.8 | 67.7 | 123.1 | 58.6% | 21.7% | 19.7% | 19.8% | 0.4 |
 ISRG | $161B | 57.6 | 43.6 | 64.7 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 GMED | $12B | 21.7 | 18.5 | 19.5 | 67.4% | 16.3% | 12.3% | 8.9% | 0.2 |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 GH | $12B | -27.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See CERS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CERS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CERS vs TXG
Side-by-side business, growth, and profitability comparison vs 10x Genomics, Inc..
Start ComparisonCERS — Frequently Asked Questions
Quick answers to the most common questions about buying CERS stock.
What is Cerus Corporation's P/E ratio?
Cerus Corporation's current P/E ratio is -31.8x. The historical average is 18.5x.
What is Cerus Corporation's ROE?
Cerus Corporation's return on equity (ROE) is -25.6%. The historical average is -77.8%.
Is CERS stock overvalued?
Based on historical data, Cerus Corporation is trading at a P/E of -31.8x. Compare with industry peers and growth rates for a complete picture.
What are Cerus Corporation's profit margins?
Cerus Corporation has 53.5% gross margin and -17.6% operating margin.